317 related articles for article (PubMed ID: 33066143)
21. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
Kallen J; Bergsdorf C; Arnaud B; Bernhard M; Brichet M; Cobos-Correa A; Elhajouji A; Freuler F; Galimberti I; Guibourdenche C; Haenni S; Holzinger S; Hunziker J; Izaac A; Kaufmann M; Leder L; Martus HJ; von Matt P; Polyakov V; Roethlisberger P; Roma G; Stiefl N; Uteng M; Lerchner A
ChemMedChem; 2018 Sep; 13(18):1997-2007. PubMed ID: 29985556
[TBL] [Abstract][Full Text] [Related]
22. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
23. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
Coombs TC; Tanega C; Shen M; Wang JL; Auld DS; Gerritz SW; Schoenen FJ; Thomas CJ; Aubé J
Bioorg Med Chem Lett; 2013 Jun; 23(12):3654-61. PubMed ID: 23642479
[TBL] [Abstract][Full Text] [Related]
25. Selective inhibition of the kinase DYRK1A by targeting its folding process.
Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
[TBL] [Abstract][Full Text] [Related]
26. The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.
Shkreta L; Toutant J; Delannoy A; Durantel D; Salvetti A; Ehresmann S; Sauvageau M; Delbrouck JA; Gravel-Trudeau A; Comeau C; Huard C; Coulombe-Huntington J; Tyers M; Grierson D; Boudreault PL; Chabot B
Oncotarget; 2024 May; 15():313-325. PubMed ID: 38753413
[TBL] [Abstract][Full Text] [Related]
27. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment.
Zu M; Li C; Fang JS; Lian WW; Liu AL; Zheng LS; Du GH
Molecules; 2015 Nov; 20(11):19735-47. PubMed ID: 26540031
[TBL] [Abstract][Full Text] [Related]
28. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
29. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
30. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
[TBL] [Abstract][Full Text] [Related]
31. New targeted therapies for anaplastic thyroid cancer.
Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
[TBL] [Abstract][Full Text] [Related]
32. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
[TBL] [Abstract][Full Text] [Related]
33. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
34. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
35. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
36. Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
Němec V; Maier L; Berger BT; Chaikuad A; Drápela S; Souček K; Knapp S; Paruch K
Eur J Med Chem; 2021 Apr; 215():113299. PubMed ID: 33636538
[TBL] [Abstract][Full Text] [Related]
37. DYRK1A kinase inhibitors with emphasis on cancer.
Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
[TBL] [Abstract][Full Text] [Related]
38. DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
Schröder M; Bullock AN; Fedorov O; Bracher F; Chaikuad A; Knapp S
J Med Chem; 2020 Sep; 63(18):10224-10234. PubMed ID: 32787076
[TBL] [Abstract][Full Text] [Related]
39. SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.
Tiek D; Wells CI; Schröder M; Song X; Alamillo-Ferrer C; Goenka A; Iglesia R; Lu M; Hu B; Kwarcinski F; Sintha P; de Silva C; Hossain MA; Picado A; Zuercher W; Zutshi R; Knapp S; Riggins RB; Cheng SY; Drewry DH
Curr Res Chem Biol; 2023; 3():. PubMed ID: 38009092
[TBL] [Abstract][Full Text] [Related]
40. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
